Participating Companies

AcelRx Pharmaceuticals, Inc.
[ACRX]
US$273 MM MCap
Launched DSUVIA (sufentanil sublingual tablet 30 mcg) in the US in 2019 for acute pain severe enough to require opioid analgesic (adult patients in certified medically supervised healthcare settings). Also developing Zalviso (Ph 3 completed) in the US as an innovative patient-controlled analgesia system for moderate-to-severe acute pain in medically supervised settings. [more information]

Adrenomed AG
Precision medicine, cardiovascular and Sepsis, Adrecizumab Ph 2, biomarker-guided, monoclonal antibody for septic shock; final data released late November:
Early application of Adrecizumab leads to a rapid and statistically significant improvement of fluid balance, systemic organ function and > 50% relative reduction of all cause mortality after 28 days and 90 days compared to placebo on top of SoC.
[more information]

Affibody
Proprietary Affibody® molecules and Albumod platforms. Lead candidate is an IL-17 with positive Ph2 52wk data in psoriasis and Ph2 IND for lead indication uveitis will be filed in Q1 2021. In addition, the company has an ongoing relationship with Inmagene in China. Backed by Investor AB. [more information]

Affimed N.V.
[AFMD]
US$657 MM MCap
NK cell engager AFM13 (CD30/CD16A) to enter a Phase 2 registration study in CD30-positive peripheral T cell lymphoma and an investigator-sponsored study by MDACC of AFM13 combined with allogeneic NK cells in relapsed/refractory CD30-positive lymphoma. [more information]

AM-Pharma B.V.
Results from Ph 2 in 300+ pts demonstrated improvement of 40%+ OS in recAP group. Initiated Ph 3 in Q4 2020; TL safety & futility analysis on first 400 pts exp YE2021. Expects to complete tgt enrollment & announce primary endpoint data of 28-day all-cause mortality in 2023. [more information]

Antev
Phase 3 ready, Teverelix, a long acting injectable peptide GnRH antagonist. Lead indication for prostate cancer, followed by benign prostatic hyperplasia (BPH), acute urinary retention (AUR), uterine fibroids and endometriosis. Over 450 subjects have been dosed over 850 times to date with no serious adverse reactions and good local tolerance. [more information]

Apexigen
CD40 agonist mAb; 170+ pts dosed (mono & combi settings). 7 ongoing Ph 2s, undisclosed ocular disease program in Ph 3. AACR: Ph 1b data (w/Parker Inst); collabs w/BMY, MDACC, Yale, et al [more information]

Aptorum Group
[APM]
US$117 MM MCap
Aptorum is Hong Kong based, US listed company (Mcap $100m) focused on generating late stage clinical candidates by developing already approved drugs for new orphan indications, as well as infectious diseases.
Pipeline –
• SACT-1 for Neuroblastoma – ph2/3 trial planned for 2H’20
• SACT-COV19 – COVID-19 treatment - preclinical [more information]

AsclepiX Therapeutics
AXT107 demonstrated efficacy and durability in rabbit and mouse models that is superior to standard of care Eylea. [more information]

Bellus Health
[BLU]
US$265 MM MCap
BELLUS' lead product candidate, BLU-5937, is being developed for the treatment of chronic cough (Phase II announced July 2020) and chronic pruritus (Phase II planned to begin 1H20). [more information]

BerGenBio
[BGBIO:OS]
NKr3,076 MM MCap
Developing first-in-class selective Axl kinase inhibitors for liquid and solid cancers, lead candidate is bemcentinib (BGB324) in four company-sponsored trials. [more information]

Biohaven Pharmaceuticals, Inc
[BHVN]
US$5,261 MM MCap
NURTEC® ODT approved in 1Q20. Topline results expected 1Q20 in Ph 3 study of troriluzole for migraine prevention. Topline results expected 2Q20 in Ph 2/3 study of troriluzole for OCD. ~$600M total in cash on hand, including recent $282.3M raise to support NURTEC ODT launch. [more information]

BioXcel Therapeutics, Inc.
[BTAI]
US$1,230 MM MCap
BXCL501 (sublingual dexmedetomidine): Met primary, key secondary and exploratory endpoints in two pivotal Phase 3 trials for the for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). Phase 1b/2 trial (TRANQUILITY) ongoing for the acute treatment of agitation associated with geriatric dementia. [more information]

CASI Pharmaceuticals Inc.
[CASI]
US$441 MM MCap
Co-commercial asset CNCT-19/CD19 CAR-T (partnered w/ Juventas): ongoing Ph 1 trials in B-NHL and B-ALL, exp to initiate registration trials by YE 2020. Exp to initiate Ph 1 study for CID-103 (anti-CD38 mAb) in EU in Q1 2021. [more information]

Catabasis Pharmaceuticals Inc
[CATB]
US$50 MM MCap
Rare disease pipeline, with lead product Edasalonexent in Ph 3 trial in Duchenne muscular dystrophy regardless of mutation type. North Star Ambulatory Assessment as the primary endpoint based on Phase 2 results and FDA input. Top-line results expected in 2020. [more information]

Catalyst Pharmaceuticals, Inc.
[CPRX]
US$376 MM MCap
Firdapse approved for Lambert-Eaton Myasthenic Syndrome (LEMS) with 3Q20 revenue of $29.2M. Top SMA Type 3 proof of concept trial expected to readout by YE 2020. Firdapse long acting formulation development continues. Studies for 2 additional neuromuscular indications are expected to commence by YE 2020. [more information]

Celldex Therapeutics, Inc.
[CLDX]
US$796 MM MCap
I-O pipeline of Abs, ADCs, immune system modulators and vaccines targeted to specific patient populations. STIC data on anti-CD40; collab with Merck. [more information]

CellMax Life
The company is currently focused on colorectal cancer (CRC) screening using the clinically validated CMx platform, a blood biopsy test platform that detects pre-cancerous lesions (adenomas) in as little as two teaspoons of blood (less than 10mL). [more information]

CerSci Therapeutics
Developing a new generation of non-opioid medicines to treat acute post-operative and chronic neuropathic pain. Lead program in Phase 1 (MAD/SAD/Food Effect), CT-044, targeting reactive species that cause neuronal ion channel hyper-sensitization, known to trigger pain. [more information]

Enterin
Developer of novel drugs intended to repair the dysfunctional gut-brain axis. The company's drugs displaces α-synuclein aggregates and restores normal signaling between the gut and the brain, enabling patients with Parkinson's disease and other neurodegenerative conditions to have a better the quality of life. [more information]

ESSA Pharma Inc.
[EPIX]
US$479 MM MCap
1Q20 IND submission for lead asset, EPI-7386, a small molecule targeting n-terminal domain of androgen receptor for mCRPC. First patient dosed in EPI-7386 Phase 1 study in mCRPC patients failing second generation antiandrogens by 2Q20. [more information]

Faraday Pharmaceuticals
Chronic and acute agents to prevent cardiac and skeletal muscle loss by modulating neurohumoral pathways and restoring metabolic flexibility: lead candidate FDY-5301 Ph 3 ready for reperfusion injury following heart attack (AMI). $57M raised to date from Arch Venture Partners, Polaris Partners, WRF, Osage [more information]

Forbius
Selective inhibitors of TGF Beta & EGFR pathways. AACR: (+) Ph 1 data. 3 ongoing Ph 2 trials (SCCHN, NSCLC, TNBC); addl Ph 1 trials in IO, Systemic Sclerosis & Myelofibrosis [more information]

Freenome Holdings, Inc.
Biotechnology diagnostics company utilizing its deep expertise in molecular biology with advanced computational biology and machine learning techniques; the company pioneered a comprehensive multiomics platform for early cancer detection through a routine blood draw. At ASCO GI 2020, demonstrated a sensitivity of 94% and specificity of 94% for early-stage (I/II) colorectal adenocarcinoma. [more information]

Galera Therapeutics
[GRTX]
US$253 MM MCap
Clinical stage biopharmaceutical company focusing on transforming radiotherapy in cancer. Lead asset GC4419 is a potent, highly selective small molecule dismutase mimetic being developed for severe oral mucositis, currently in Phase 3 with Breakthrough Therapy Designation. Topline results expected in 1H21. Top line results in Phase 1b/2a in second asset, GC4419 in pancreatic cancer expected in 2H20. GC4419 expected to initiate in Phase 1b/2a in lung cancer in 2H20. [more information]

Genfit SA
[GNFTF]
US$199 MM MCap
Development of elafibranor in PBC: ongoing enrollment for Ph 3 clinical trial ELATIVE™. Commercialization of NIS4™ for NASH diagnosis. [more information]

HaemaLogiX
Proprietary, differentiated B cell targets engaged via antibody and CAR-T programs
KappaMab & LambdaMab target activated plasma cell antigens (KMA/LMA); KappaMab plus RevDex vs. RevDex Ph 2b in MM, data 1H20; Kappa CAR-T Ph 1 Q120 in MM; Capacity for dual-targeting via CD-19, BCMA, etc; LambdaMab in preclinical for amyloidosis [more information]

Hutchison China MediTech Ltd ("Chi-Med")
[HCM]
US$4,566 MM MCap
Chi-Med has a portfolio of 8 drugs in clinical development from own discovery engine in its Innovation platform and a cash generating Commercial platform with 2,500+ sales reps. Global collaboration with AstraZeneca in two registration enabling studies with savolitinib in Tagrisso refractory lung cancer that is MET+ and EGFRm+ (global) and MET Exon 14 deletion NSCLC (China). [more information]

Impact Therapeutics Inc
Impact Therapeutics is a privately held clinical-stage biopharmaceutical company and dedicates to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. [more information]

Invetx
Invetx is building the world’s premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. The Invetx team of highly experienced R&D leaders from both human biotech and animal health is supported by best-in-class biotechnology partners and an extensive network of industry experts, veterinary scientists and clinicians. Invetx is a private company headquartered in Boston, Massachusetts. [more information]

Iovance Biotherapeutics
[IOVA]
US$6,544 MM MCap
Late-stage cell therapy company utilizing proprietary autologous tumor infiltrating lymphocytes (TILs) to attack solid tumors. The company is conducting pivotal stage trials in metastatic melanoma and advanced cervical cancer with BLAs expected 2020. [more information]

ISA Pharmaceuticals BV
is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. [more information]

Junshi Biosciences
[1877:HK]
Has a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic, autoimmune, neurological, and infectious diseases. Product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai and Suzhou. JS001, or toripalimab, is approved by the NMPA and the first marketed anti-PD-1 mAb antibody self-developed by a PRC company. [more information]

Kadmon Holdings, Inc.
[KDMN]
US$904 MM MCap
Announced pos. primary analysis results (May 2020) in pivotal trial of ROCK inhibitor-KD025 (Belumosudil) in cGVHD pts receiving 2+ prior therapy lines; ORRs of 73% and 74% in 200mg QD and 200mg BID arms, respectively. Belumosudil is being reviewed under Real-Time Oncology Review (RTOR) Pilot Program by the FDA; NDA submission exp Q4 2020. Enrolling pts in Ph 2 trial (sys. sclerosis). [more information]

Kineta Inc.
Kineta (Private) - wholly owned preclinical anti-VISTA (innate immune target) antibody reprograms the tumor microenvironment and is differentiated from other immunotherapies by blocking suppressive cells in cold tumors. $360M+ deal with Genentech for KCP506, Ph1 non-opioid for chronic pain. [more information]

Landos Biopharma
Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile. Lead asset BT-11 Phase 2 interim read out in mid-2020 in UC. [more information]

Lineage Cell Therapeutics Inc.
[LCTX]
US$372 MM MCap
Cell therapy company with 3 clnical programs 1) OpRegen, an RPE transplant therapy in Ph1/2a development for the treatment of dry-AMD. 2) OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries with Orphan and RMAT designations. 3) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Ph 1 for NSCLC conducted by CRUK. [more information]

Marker Therapeutics
[MRKR]
US$92 MM MCap
A clinical-stage immuno-oncology company with the potential to significantly disrupt the current cell therapy landscape. Marker's current MultiTAA cell therapy is looking to initiate a Phase II study in AML in 2020 with enrollment completion anticipated in 2H20. The company also has a T-cell vaccine program, currently being studied in breast cancer. [more information]

Maxcyte
[MXCT:LN]
global cell therapy company providing proprietary non-viral cell engineering technology for the next generation of cell-based therapies including gene editing and immuno-oncology. MaxCyte may be seen as a play on the cell therapy market with its blue chip client base. [more information]

Minoryx Therapeutics
Oral PPARg agonist, MIN-102, in Pivotal Ph 2/3 for X-linked ALD and Ph 2 Friedrich’s Ataxia; data for both expected by end of 2020. VC investors include Kurma, Ysios, Fund+, Roche, Idinvest, etc
[more information]

Neoleukin Therapeutics
[NLTX]
US$535 MM MCap
Lead program NL-201: is a dual-acting IL-2 and IL-15 agonist immunotherapy for cancer, designed to improve tolerability and activity by eliminating the alpha receptor binding interface (IND completed 4Q20). First de novo protein therapeutic ever created. [more information]

NeuroRx
Leading Relief Therapeutics Ph 2 trial of Aviptadil to treat COVID-19 induced ARDS in the US. In Phase 3 with readout expected mid-January 2021. Also developing first Glx targeted antidepressant to address suicidality in bipolar depression. NRX-101 is in Ph 2b/3 development, (Breakthrough Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w Acute Suicidal Ideation and Behavior. [more information]

NexImmune, Inc.
Multi-antigen-specific T cell therapy. Synthetic nanoparticles decorated w a combo of multiple tumor relevant antigens and co-stimulatory signals engaging directly w targeted T cells. Two Ph 1's ongoing. [more information]

NorthSea Therapeutics
First-in class, oral, structurally engineered fatty acids [SEFAs] addressing NASH and associated metabolic disorders via unique targeting of pathways regulating metabolism, oxidative stress, inflammation, and fibrosis. $40m Series B (Jan 2020) with venBio Partners (lead) and Sofinnova Investments. [more information]

Oncopeptides AB
[ONCO:ST]
SKr10,768 MM MCap
Potential approval for Melflufen (Ygalo) 1Q21. First in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. H2H versus Pomalyst completed enrollment Sep '20. [more information]

OnKure Therapeutics, Inc.
Developing epigenetic cancer therapies including HDAC inhibitors. Lead asset OKI-179 is a class 1 HDAC inhibitor in Ph 1. [more information]

PAION AG
[PA8:DE]
Remimazolam: short-acting anesthetic. Ph 3 study in procedural sedation in US. Safety data in ASA III/IV patients in Ph 3 colonoscopy study and Ph 3 bronchoscopy study. US approval filed by partner Cosmo Pharmaceuticals in June 2019. Initiated Ph 3 in general anesthesia in EU in July 2018, exp completion 2020. [more information]

Paradigm BioPharma
[PBIGF]
US$407 MM MCap
Launching Ph 3 in 2020 in OA pts w/bone marrow edema lesions (BML). Positive Ph2b results in subjects w/OA & BML - stat sig improvement on pain reduction & BML volume/grade reductions on MRI. Q12020: initial data from compassionate use trial (ex-NFL subjects w/OA) and joint IND submission to FDA/EMA for pivotal trial in Mucopolysaccharidosis. Exp AUS rev-gen in Q3 20. [more information]

PharmaMar SA
[PHM:ES]
Revenue generating with marine-derived and novel MoA oncology products. Yondelis (soft tissue sarcoma and ovarian cancer) commercialized with direct sales-force in EU and partnership in US with Janssen. Signed licensing agreement with Jazz Pharma for lurbinectedin in the US - upfront payment of $200M, $100mm on approval and up to $550M sales milestones. [more information]

Pharming Group NV
[PHARM:AS]
€752 MM MCap
recent in-license from Novartis of late stage drug Leniolisib for APDS (ultra-rare immunodeficiency condition), rhC1INH for new larger indications including COVID-19, pre-eclampsia, AKI and additional pipeline product from technology platform: recombinant alpha-Glucosidase for Pompe disease. [more information]

Pharvaris
Developing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor, currently in Ph 1 trial for the treatment of HAE. [more information]

Photocure ASA
[PHO:OS]
NKr2,734 MM MCap
Photocure is a revenue-generating commercial stage company focused on urology. Lead product Hexvix/Cysview is an optical imaging agent for improved detection, reduced disease recurrence and progression rates of bladder cancer. [more information]

Pieris Pharmaceuticals, Inc.
[PIRS]
US$143 MM MCap
Anticalins (engineered lipocalin proteins) for resp & onco diseases. Imminent data for AZN-partnered PRS-060 inhaled IL4 for mod-to-severe asthma. Cash of $128MM in the bank as of March 2019. [more information]

Protagonist Therapeutics
[PTGX]
US$889 MM MCap
Proprietary peptide technology platform to develop oral targeted therapy-based drugs and injectables for rare diseases. PTG-300 injectable hepcidin mimetic Ph 2 trials ongoing in polycythemia vera and hereditary hemochromatosis; positive updated Ph 2 results in PV presented at ASH 2020. PN-943 oral GI-restricted alpha-4-beta-7 antagonist Ph 2 in ulcerative colitis study sites activated; PTG-200, partnered w/ Janssen, oral GI-restricted IL-23R antagonist Ph 2 Crohn’s disease study ongoing. [more information]

Ryvu Therapeutics
[RVU:WAR]
Potential first in class CDK8 inhibitor for leukemias, lymphomas, and solid tumors in Ph1b in AML and high-risk MDS, PIM/FLT3 kinase inhibitor in Ph 1/2 in AML (partnered w Menarini). Data in 2020. Early stage pipeline addressing emerging solid tumor targets. [more information]

Savara Inc.
[SVRA]
US$89 MM MCap
Orphan lung disease Company; Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP); study expected to start Q1 2021. Also, Phase 3 trial, AVAIL, is evaluating persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis. Top line data are expected early in 2021 [more information]

Secarna Pharmaceuticals GmbH
Secarna's uniquely efficient LNAplus™ discovery process is fueled by their proprietary and streamlined Oligofyer™ bioinformatics systems large in-house cell library and own in vitro screening assays. [more information]

Selecta Biosciences, Inc.
[SELB]
US$452 MM MCap
Immune tolerance platform (ImmTOR) developed in combo with rare disease therapies. SEL-212 (chronic refractory gout, out-licensed to Sobi) DISSOLVE Ph 3 program ongoing. Gene tx pipeline in preclinical development with ImmTOR where re-dosing require. AskBio and Sarepta collabs. [more information]

Sol-Gel Technologies Ltd.
[SLGL]
US$239 MM MCap
Commercializing branded generic topical drug products (skin diseases). Two positive Phase 3 programs, both with PDUFA dates in 2021: Epsolay has potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product for rosacea (PDUFA date on April 26th). Twyneo has potential to be the first acne treatment that contains fixed dose combination of BPO and tretinoin (PDUFA date on August 1st). [more information]

Sonnet Biotherapeutics, Inc.
[SONN]
US$49 MM MCap
Sonnet's interleukin-based candidate has been shown to enhance pK (up to 10 fold) and improve tumor delivery with an increase in in vivo efficacy (30 fold) as demonstrated in a mice tumor model. The Sonnet platform de-risks the use of interleukins by greatly extending their in vivo half-life, while also improving their specificity to tumor tissue. [more information]

SphingoTec GmbH
The tests are being implemented on the Company’s own point-of-care immunoassay analyzer platform acquired form Samsung in 2018 that is fully developed and was originally launched in 2012 and was sold more than 1,800 times since then. [more information]

sterna biologicals
By targeting transcription factors that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company’s proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes to address related diseases more effectively. Sterna currently has four programs in phase 2 development. [more information]

Strongbridge Biopharma
[SBBP]
US$191 MM MCap
Rare diseases; Keveyis for PPP revs ~21.7M for 2019 and $26 - $27M for 2020. Recorlev for endogenous Cushing's syndrome Ph 3 published with topline placebo-controlled Ph 3 3Q20. [more information]

Sutro Biopharma
[STRO]
US$996 MM MCap
FolRα-targeting ADC (STRO-002) Phase 1, additional dose escalation data in 4Q20. CD74-targeting ADC (STRO-001) Phase 1, additional dose escalation data in 4Q20. BMS collaboration Phase 1 clinical development update for CC-99712 (BCMA-targeting ADC). Merck collaboration update in 2020 on first cytokine derivative program. [more information]

Syneos Health
[SYNH]
US$7,840 MM MCap
Syneos Health® is an end-to-end, fully integrated biopharmaceutical solutions company that works differently. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial, work together to create customer success. Our unique Biopharmaceutical Acceleration Model delivers value across the small to mid-size to large customer continuum. [more information]

Targovax
[TRVX]
Preliminary Ph1b data of OV ONCOS-102+chemo in mesothelioma results: combo mPFS=8.4 mos. vs. control mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Upcoming milestones: updated clinical & immune data in Ph2 mesothelioma (1H20); preclinical data on next-gen OV w/ double transgenes (1H20); and clinical data from Ph1 melanoma study, part 2 with extended dosing (2H20). [more information]

Teon Therapeutics
Pipeline of next-generation cancer therapeutics targeting GPCRs including a highly-specific A2B antagonist and EP4 antagonist, both slated to enter Phase 1b trials in 2021. [more information]

Tessa Therapeutics
Ongoing Ph III (nasopharyngeal cancer), upcoming pivotal Ph II (Hodgkin lymphoma), and multiple other clinical-stage programs. GMP facility under construction. Key collaborations: Baylor, Parker Inst., St. Jude Children’s, and JV in China. [more information]

Vaccitech Limited
Proprietary ChAdOx (prime) and MVA (boost) technology platform induces and maintains CD8+ T-cells at the maximum levels published to date. Ph1/2 data for HPV and HBV immunotherapies expected 2H20. Encouraging prostate cancer, 5T4 immunotherapeutic data recently released. Ph1/2 NSCLC MAGE-NYESO immunotherapeutic enters clinic in Q1 2021. ChAdOx COVID-19 vaccine out-licensed to Oxford Uni/AstraZeneca with post-pandemic revenue stream. $150M funding at Jenner Institute and company raised $48M since formation [more information]

Vericel Corporation
[VCEL]
US$1,824 MM MCap
Advanced cell therapy; marketing MACI (cartilage repair) and Epicel (skin replacement) in TAMs of $2b+. Q3 MACI and Epicel revs of $31.1m. Reported record third quarter MACI revenue and total revenues, and the second highest quarterly Epicel revenue in history. NexoBrid PDUFA date of June 29, 2021. [more information]

Verrica Pharmaceuticals
[VRCA]
US$312 MM MCap
Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for viral skin diseases requiring medical attention. Lead product, VP-102 for molluscum contagiosum has a PDUFA date of July 13, 2020. Phase 2 data in external genital warts expected in 2H20. Initiation of Phase 3 in common warts in 1H20 and initiation of Phase 2 in plantar warts in mid-2020. [more information]

Viela Bio
[VIE]
US$1,958 MM MCap
UPLINZA® (inebilizumab, anti-CD19 mAb) on the market for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Additional trials with inebilizumab ongoing, including Ph 3 trials in myasthenia gravis and IgG4-related disease. VIB7734, anti-ILT7 mAb, Ph 2 trial to initiate in 1H21. Ph 2 trials ongoing for VIB4920 (Anti-CD40L-Tn3 Fusion Protein) in Sjogren's Syndrome and kidney transplant rejection. [more information]

Vyome Therapeutics Inc.
$22M fund raise Jan '19. Advanced lead asset VB-1953 to Ph 2 for moderate to severe acne. Pipeline DART - dual action overcoming antimicrobial resistance - and MRT - patented antifungal platform. Treat drug-resistant skin pathogens. [more information]